Sublingual Dexmedetomidine for Treating Opioid Withdrawal

NCT05712707 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

160

Enrollment

OTHER

Sponsor class

Conditions

Opioid Use Disorder
Opioid Withdrawal

Interventions

DRUG: BXCL501 (180 micrograms)
DRUG: BXCL501 (240 micrograms)
OTHER: Placebo
OTHER: Lofexidine (Positive Control)

Sponsor

New York State Psychiatric Institute

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]